Kenvue /$KVUE
1D1W1MYTD1Y5YMAX
Capital at risk
About Kenvue
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
- Ticker
- $KVUE
- Sector
- Consumer Essentials
- Primary listing
- NYSE
- Employees
- 21,890
- Headquarters
- Summit, United States
- Website
- www.kenvue.com
Kenvue Metrics
BasicAdvanced
$34B
20.98
$0.85
0.43
$0.83
4.71%
Price and volume
Market cap
$34B
Beta
0.43
52-week high
$20.13
52-week low
$14.02
Average daily volume
25M
Dividend rate
$0.83
Financial strength
Current ratio
1.005
Quick ratio
0.611
Long term debt to equity
0.679
Total debt to equity
0.816
Dividend payout ratio (TTM)
96.02%
Interest coverage (TTM)
6.52%
Profitability
EBITDA (TTM)
3,407
Gross margin (TTM)
58.44%
Net profit margin (TTM)
10.76%
Operating margin (TTM)
19.55%
Effective tax rate (TTM)
25.42%
Revenue per employee (TTM)
$700,000
Management effectiveness
Return on assets (TTM)
6.99%
Return on equity (TTM)
15.58%
Valuation
Price to earnings (TTM)
20.977
Price to revenue (TTM)
2.219
Price to book
3.24
Price to tangible book (TTM)
-4.81
Price to free cash flow (TTM)
17.863
Free cash flow yield (TTM)
5.60%
Free cash flow per share (TTM)
0.998
Dividend yield (TTM)
4.67%
Forward dividend yield
4.71%
Growth
Revenue change (TTM)
1.76%
Earnings per share change (TTM)
14.85%
3-year revenue growth (CAGR)
-0.02%
3-year earnings per share growth (CAGR)
-7.00%
What the Analysts think about Kenvue
Analyst ratings (Buy, Hold, Sell) for Kenvue stock.
Analyst projections of the future price of Kenvue stock.
Bulls say / Bears say
Kenvue delivered its third consecutive quarter of net and organic sales growth in Q2 2026; sales rose 3.0%, organic sales increased 1.6%, and adjusted EPS grew 7% to $0.31. (Reuters)
Several core franchises showed momentum: Skin Health and Beauty sales increased 5.1%, Self Care grew 2.2%, and Kenvue reported improved U.S. Tylenol performance alongside market-share gains for Zyrtec and Pepcid. (Reuters)
The pending Kimberly-Clark combination gives shareholders a defined cash-and-stock monetization path, with the companies targeting completion in the fourth quarter of 2026 and expected cost savings from the transaction. (SEC)
Kenvue’s Q2 adjusted gross margin fell to 60.2% from 60.9%, while inflation, tariffs and currency-related costs contributed to a slight earnings and revenue miss versus analyst expectations. (Reuters)
Tylenol-related litigation risk has increased: in July 2026, the Second Circuit vacated a prior dismissal and remanded acetaminophen cases for further proceedings, while Kenvue said it cannot reasonably estimate potential liability. (SEC)
The Kimberly-Clark transaction remains subject to outstanding regulatory approvals, including EU review, and Kenvue has suspended forward guidance because of the pending deal, increasing uncertainty around timing and standalone valuation. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Kenvue Financial Performance
Revenues and expenses
Kenvue Earnings Performance
Company profitability
Upcoming events
Kenvue News
AllArticlesVideos
Funds containing Kenvue
AllEURGBPUSD
Fund name | Fund size | $KVUE weighting |
|---|---|---|
SPDR S&P US Dividend Aristocrats€SPYD | €3.3B | 1.48% |
SPDR S&P US Dividend Aristocrats£USDV | £2.8B | 1.48% |
VanEck Morningstar Wide Moat€GMVM | €407M | 1.35% |
VanEck Morningstar Wide Moat£MOGB | £354M | 1.35% |
iShares S&P 500 Consumer Staples Sector€2B7D | €450M | 1.16% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.